Patents by Inventor Stanley D'Andrea

Stanley D'Andrea has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
    Patent number: 10125148
    Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    Type: Grant
    Filed: February 19, 2014
    Date of Patent: November 13, 2018
    Assignee: ViiV HEALTHCARE UK (NO. 5) LIMITED
    Inventors: Timothy P. Connolly, Stanley D'Andrea, John F. Kadow, David R. Langley, B. Narasimhulu Naidu, Manoj Patel, Kevin Peese, Michael A. Walker, Zhongyu Wang, Zhizhen Barbara Zheng
  • PYRAZOLOPYRIMIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    Publication number: 20170008909
    Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    Type: Application
    Filed: February 19, 2014
    Publication date: January 12, 2017
    Inventors: Timothy P. CONNOLLY, Stanley D'ANDREA, John F. KADOW, David R. LANGLEY, B. Narasimhulu NAIDU, Manoj PATEL, Kevin PEESE, Michael A. WALKER, Zhongyu WANG, Zhizhen Barbara ZHENG
  • Inhibitors of human immunodeficiency virus replication
    Patent number: 9540393
    Abstract: The disclosure generally relates to compounds of formula (I), including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: January 10, 2017
    Assignee: ViiV HEALTHCARE UK (NO.5) LIMITED
    Inventors: B. Narasimhulu Naidu, Manoj Patel, Stanley D'Andrea, Zhizhen Barbara Zheng
  • Inhibitors of Human Immunodeficiency Virus Replication
    Publication number: 20160039844
    Abstract: The disclosure generally relates to compounds of formula (I), including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    Type: Application
    Filed: March 7, 2014
    Publication date: February 11, 2016
    Inventors: B. Narasimhulu NAIDU, MANOJ PATEL, STANLEY D'ANDREA, ZHIZHEN BARBARA ZHENG
  • Inhibitors of human immunodeficiency virus replication
    Patent number: 9034882
    Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: May 19, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: Annapurna Pendri, David R. Langley, Samuel Gerritz, Guo Li, Weixu Zhai, Stanley D'Andrea, Manoj Patel, B. Narasimhulu Naidu, Kevin Peese, Zhongyu Wang
  • Inhibitors of human immunodeficiency virus replication
    Patent number: 9006235
    Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: April 14, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: Zhizhen Barbara Zheng, Stanley D'Andrea, David R. Langley, B. Narasimhulu Naidu
  • Inhibitors of human immunodeficiency virus replication
    Patent number: 8906929
    Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    Type: Grant
    Filed: August 5, 2013
    Date of Patent: December 9, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: B. Narasimhulu Naidu, Manoj Patel, Stanley D'Andrea, Zhizhen Barbara Zheng, Timothy P. Connolly, David R. Langley, Kevin Peese, Zhongyu Wang, Michael A. Walker, John F. Kadow
  • Compound for the treatment of hepatitis C
    Patent number: 8716275
    Abstract: The present invention provides (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1 -methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl) carbonyl)-1,1a,2,12b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide (formula I), including pharmaceutically acceptable salts, as well as compositions and methods of using the compound. The compound has activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: October 15, 2012
    Date of Patent: May 6, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Zhizhen Barbara Zheng, Stanley D'Andrea
  • Inhibitors of Human Immunodeficiency Virus Replication
    Publication number: 20140051692
    Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    Type: Application
    Filed: August 5, 2013
    Publication date: February 20, 2014
    Inventors: B. Narasimhulu Naidu, Manoj Patel, Stanley D'Andrea, Zhizhen Barbara Zheng, Timothy P. Connolly, David R. Langley, Kevin Peese, Zhongyu Wang, Michael A. Walker, John F. Kadow
  • Inhibitors of Human Immunodeficiency Virus Replication
    Publication number: 20130237499
    Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    Type: Application
    Filed: March 1, 2013
    Publication date: September 12, 2013
    Applicant: Bristol-Myers Squibb Company
    Inventors: Zhizhen Barbara Zheng, Stanley D'Andrea, David R. Langley, B. Narasimhulu Naidu
  • Inhibitors of Human Immunodeficiency Virus Replication
    Publication number: 20130231331
    Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    Type: Application
    Filed: March 1, 2013
    Publication date: September 5, 2013
    Inventors: Annapurna Pendri, David R. Langley, Samuel Gerritz, Guo Li, Weixu Zhai, Stanley D'Andrea, Manoj Patel, B. Narasimhulu Naidu, Kevin Peese, Zhongyu Wang
  • Inhibitors of hepatitis C virus
    Patent number: 8343477
    Abstract: Macrocyclic peptides are disclosed having the general formula: wherein R3, R?3, R4, R6, R?, X, Q and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Grant
    Filed: October 25, 2007
    Date of Patent: January 1, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Stanley D'Andrea, Zhizhen Barbara Zheng, Paul Michael Scola
  • Hepatitis C virus inhibitors
    Patent number: 8003604
    Abstract: Macrocyclic peptides having the general formula: are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Grant
    Filed: November 14, 2007
    Date of Patent: August 23, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: Alan Xiangdong Wang, Barbara Zhizhen Zheng, Stanley D'Andrea, Nicholas A. Meanwell, Paul Michael Scola
  • Hepatitis C virus inhibitors
    Patent number: 7888464
    Abstract: Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Grant
    Filed: November 14, 2007
    Date of Patent: February 15, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: Alan Xiangdong Wang, Barbara Zhizhen Zheng, Stanley D'Andrea, Qian Zhao, Paul Michael Scola
  • Hepatitis C virus inhibitors
    Patent number: 7772183
    Abstract: Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Grant
    Filed: October 11, 2006
    Date of Patent: August 10, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: David J. Carini, Barry L. Johnson, Zhizhen Barbara Zheng, Stanley D'Andrea, Paul Michael Scola
  • Hepatitis C virus inhibitors
    Patent number: 7763584
    Abstract: Macrocyclic peptides having the general formula: are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Grant
    Filed: November 14, 2007
    Date of Patent: July 27, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Alan Xiangdong Wang, Barbara Zhizhen Zheng, Stanley D'Andrea, Nicholas A. Meanwell, Paul Michael Scola
  • Hepatitis C virus inhibitors
    Patent number: 7741281
    Abstract: Macrocyclic peptides are disclosed having the general formula: wherein R?, R3, R3?, R4, R6, X, Q, and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Grant
    Filed: November 1, 2006
    Date of Patent: June 22, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Stanley D'Andrea, Zhizhen Barbara Zheng, Jeffrey Allen Campbell, Fiona McPhee, Andrew Charles Good, Paul Michael Scola
  • HEPATITIS C VIRUS INHIBITORS
    Publication number: 20090274648
    Abstract: Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Application
    Filed: November 14, 2007
    Publication date: November 5, 2009
    Inventors: Alan Xiangdong Wang, Barbara Zhizhen Zheng, Stanley D'Andrea, Qian Zhao, Paul Michael Scola
  • HEPATITIS C VIRUS INHIBITORS
    Publication number: 20080159982
    Abstract: Macrocyclic peptides having the general formula: are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Application
    Filed: November 14, 2007
    Publication date: July 3, 2008
    Inventors: Alan Xiangdong Wang, Barbara Zhizhen Zheng, Stanley D'Andrea, Nicholas A. Meanwell, Paul Michael Scola
  • HEPATITIS C VIRUS INHIBITORS
    Publication number: 20080145334
    Abstract: Macrocyclic peptides having the general formula: are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Application
    Filed: November 14, 2007
    Publication date: June 19, 2008
    Inventors: Alan Xiangdong Wang, Barbara Zhizhen Zheng, Stanley D'Andrea, Nicholas A. Meanwell, Paul Michael Scola